Eli Lilly's Alzheimer Drug Fails Final-Stage Trial

Bloomberg Video

Nov.23 -- Eli Lilly & Co. announced that its experimental Alzheimer's treatment, Solanezumab, failed in a final-stage trial, sending shares sharply lower in pre-market trading. Bloomberg's Drew Armstrong looks at what comes next for the drugmaker on "Bloomberg Daybreak: Americas."